TY - JOUR
T1 - Diabetic retinopathy
T2 - Current understanding, mechanisms, and treatment strategies
AU - Duh, Elia J.
AU - Sun, Jennifer K.
AU - Stitt, Alan W.
N1 - Funding Information:
The authors would like to acknowledge financial support from the NIH NEI (EY022383 and EY022683), Fight for Sight (UK), The Sir Jules Thorn Trust, DEL/SFI, Wolfson Foundation, The Royal Society, NIH NEI R01 (EY024702), JDRF 3-SRA-2014-264-M-R, and Massachusetts Lions Eye Research Fund. The authors are grateful to Zhenhua Xu for assistance with preparation of the figures.
Publisher Copyright:
© 2017 American Society for Clinical Investigation. All rights reserved.
PY - 2017/7/20
Y1 - 2017/7/20
N2 - Diabetic retinopathy (DR) causes significant visual loss on a global scale. Treatments for the vision-threatening complications of diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) have greatly improved over the past decade. However, additional therapeutic options are needed that take into account pathology associated with vascular, glial, and neuronal components of the diabetic retina. Recent work indicates that diabetes markedly impacts the retinal neurovascular unit and its interdependent vascular, neuronal, glial, and immune cells. This knowledge is leading to identification of new targets and therapeutic strategies for preventing or reversing retinal neuronal dysfunction, vascular leakage, ischemia, and pathologic angiogenesis. These advances, together with approaches embracing the potential of preventative or regenerative medicine, could provide the means to better manage DR, including treatment at earlier stages and more precise tailoring of treatments based on individual patient variations.
AB - Diabetic retinopathy (DR) causes significant visual loss on a global scale. Treatments for the vision-threatening complications of diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) have greatly improved over the past decade. However, additional therapeutic options are needed that take into account pathology associated with vascular, glial, and neuronal components of the diabetic retina. Recent work indicates that diabetes markedly impacts the retinal neurovascular unit and its interdependent vascular, neuronal, glial, and immune cells. This knowledge is leading to identification of new targets and therapeutic strategies for preventing or reversing retinal neuronal dysfunction, vascular leakage, ischemia, and pathologic angiogenesis. These advances, together with approaches embracing the potential of preventative or regenerative medicine, could provide the means to better manage DR, including treatment at earlier stages and more precise tailoring of treatments based on individual patient variations.
UR - http://www.scopus.com/inward/record.url?scp=85052014336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052014336&partnerID=8YFLogxK
U2 - 10.1172/JCI.INSIGHT.93751
DO - 10.1172/JCI.INSIGHT.93751
M3 - Review article
C2 - 28724805
AN - SCOPUS:85052014336
SN - 2379-3708
VL - 2
JO - JCI Insight
JF - JCI Insight
IS - 14
M1 - e93751
ER -